[1] 陈婷婷, 丁蓉, 姬文莉, 等. 高敏HBV DNA检测技术在低病毒血症慢性乙型肝炎患者抗病毒疗效监测中的应用[J]. 实用肝脏病杂志, 2025,28(2):178-181.
[2] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023,26(3):457-478.
[3] 鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021,37(6):1268-1274.
[4] Lee S B, Jeong J, Park J H, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir[J]. Clin Mol Hepatol, 2020,26(3):364-375.
[5] Xie L, Liu G, Liu Y, et al. Prevalence of low-level viremia in the treatment of chronic hepatitis B in China: a systematic review and meta-analysis[J]. BMJ Open, 2025,15(6):e088756.
[6] Rajbhandari R, Nguyen V H, Knoble A, et al. Advances in the management of hepatitis B[J]. BMJ, 2025,389:e079579.
[7] Sun F, Liu Z, Wang B. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study[J]. BMC Cancer, 2021,21(1):1103.
[8] Kim T S, Sinn D H, Kang W, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia[J]. J Gastroenterol Hepatol, 2019,34(11):2028-2035.
[9] Lin W C, Lin K, Li M K, et al. Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients[J]. World J Hepatol, 2024,16(11):1321-1330.
[10] Kim J H, Sinn D H, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017,66(2):335-343.
[11] Li R, Li W, Yang Q, et al. Low-level viremia impairs efficacy of immune checkpoint inhibitors in unresectable hepatocellular carcinoma[J]. Liver Int, 2025,45(4):e70066.
[12] Lu Z, Sun Y M, Chen S, et al. Multiple low-level viraemia suggest hindered liver fibrosis regression in chronic hepatitis B patients during antiviral therapy[J]. J Viral Hepat, 2024,31(12):898-902.
[13] Xu J, Zhang Y, Zhu L, et al. Non-invasive monitoring of the impact of low-level viremia on liver fibrosis in treated chronic hepatitis B patients[J]. Infect Drug Resist, 2024,17:2751-2758.
[14] Sun Y, Wu X, Zhou J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020,18(11):2582-2591.
[15] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease[J]. J Clin Transl Hepatol, 2021,9(6):850-859.
[16] Boonstra A, Sari G. HBV cccDNA: the molecular reservoir of hepatitis B persistence and challenges to achieve viral eradication[J]. Biomolecules, 2025,15(1):62.
[17] Wei L, Ploss A. Mechanism of hepatitis B virus cccDNA formation[J]. Viruses, 2021,13(8):1463.
[18] Liu Y, Liu H, Hu Z, et al. Hepatitis B virus virions produced under nucleos (t) ide analogue treatment are mainly not infectious because of irreversible DNA chain termination[J]. Hepatology, 2020,71(2):463-476.
[19] 王雷婕, 顾智强, 许梓萌, 等. 核苷(酸)类药物经治慢性乙型肝炎患者低病毒血症发生的可能机制[J]. 中华肝脏病杂志, 2021,29(12):1151-1155.
[20] Zheng J R, Wang Z L, Feng B. Hepatitis B functional cure and immune response[J]. Front Immunol, 2022,13:1075916.
[21] Tao Y C, Wang M L, Zhang D M, et al. Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment[J]. J Viral Hepat, 2020,27(7):731-738.
[22] Shin J W, Jung S W, Lee S B, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir[J]. Am J Gastroenterol, 2018,113(7):998-1008.
[23] Chen H, Fu J J, Li L, et al. Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study[J]. J Gastroenterol Hepatol, 2024,39(1):180-184.
[24] 李彤, 孔银, 刘元元, 等. 经治慢性乙型肝炎低病毒血症患者人群特征及其相关影响因素:一项单中心横断面回顾性研究[J]. 中华肝脏病杂志, 2023,31(1):42-48.
[25] 何谱, 刘文宗. 抗病毒治疗慢性乙型肝炎患者发生低病毒血症的危险因素[J]. 肝脏, 2024,29(9):1105-1108.
[26] Cornberg M, Sandmann L, Jaroszewicz J, et al. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025,83(2):502-583.
[27] Terrault N A, Lok A S, McMahon B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018,67(4):1560-1599.
[28] He M W, Cui L, Chen D D, et al. Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: a real-world 48-week extension study[J]. Antimicrob Agents Chemother, 2025,69(3):e0182724.
[29] 刘丽萍, 邬小萍, 蔡天盼, 等. 恩替卡韦经治后低病毒血症的慢性乙型肝炎患者序贯联合富马酸丙酚替诺福韦治疗的疗效及影响因素分析[J]. 中华肝脏病杂志, 2023,31(2):118-125.
[30] 宋庆润, 高峰, 杨小平, 等. ETV与TDF联合治疗NAs经治慢性乙型肝炎低病毒血症28例48周疗效观察[J]. 肝脏, 2022,27(2):222-224.
[31] 宋承润, 李宇靖, 李兰清, 等. 恩替卡韦或富马酸丙酚替诺福韦治疗出现低病毒血症的患者可换用艾米替诺福韦进行挽救治疗[J]. 中华肝脏病杂志, 2024,32(S1):14-18.
[32] 向文耀, 李仕雄, 吕日英. 恩替卡韦治疗后慢性乙型肝炎低病毒血症患者序贯联合艾米替诺福韦治疗的效果研究[J]. 中国现代医学杂志, 2024,34(8):15-20.
[33] Zhao Q, Liu H, Tang L, et al. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy[J]. Antiviral Res, 2024,221:105782.
[34] Lim S G, Yang W L, Ngu J H, et al. Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT[J]. Clin Gastroenterol Hepatol, 2022,20(2):e228-e250.
[35] Hu Q, Qi X, Yu Y, et al. The efficacy and safety of adding on or switching to peginterferon α-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: a multicentre randomised controlled trial[J]. Aliment Pharmacol Ther, 2022,56(9):1394-1407.
[36] 王玉珊, 孔银, 刘元元, 等. 不同转换治疗策略对经治的低病毒血症慢性乙型肝炎患者疗效的影响:单中心回顾性研究[J]. 实用肝脏病杂志, 2022,25(5):633-636.
[37] Wang L, Lu J, Liu D, et al. Adding pegylated interferon-α to nucleos (t) ide analogues improves HBsAg clearance in chronic hepatitis B with low-level viremia[J]. Front Med, 2025,12:1642961.
[38] 吴迎凤, 朱树华, 周洁. 艾米替诺福韦联合聚乙二醇干扰素治疗慢性乙型肝炎低病毒血症患者疗效[J]. 中华保健医学杂志, 2025,27(1):85-88.
[39] Wu D, Kao J H, Piratvisuth T, et al. Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0[J]. Clin Mol Hepatol, 2025,31(Suppl):S134-S164. |
